The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The state of cancer treatment trials in America: A comparison of counties with and without active trials by demography and social vulnerability.
 
Margaret Kelsey Kirkwood
No Relationships to Disclose
 
Caroline Schenkel
No Relationships to Disclose
 
Suanna Steeby Bruinooge
No Relationships to Disclose
 
Mark F. Riffon
No Relationships to Disclose
 
Jeffrey M. Peppercorn
Employment - GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
 
Ishwaria M. Subbiah
Consulting or Advisory Role - MedImmune (I)
Research Funding - Abbvie (I); Amgen (I); Bayer (I); Blueprint Medicines (I); Celgene (I); Exelixis (I); Fujifilm (I); GlaxoSmithKline (I); Incyte (I); Loxo (I); Multivir (I); NanoCarrier (I); Northwest Biotherapeutics (I); Novartis (I); Pfizer (I); Takeda (I)
 
David Michael Waterhouse
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AZTherapies; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Fresenius Kabi; Gilead Sciences; Janssen Oncology; Jazz Pharmaceuticals; Lilly; McGivney Global Advisors; Merck; Mirati Therapeutics; Pfizer; Sanofi; Sanofi/Regeneron; Seagen
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Laura A. Levit
No Relationships to Disclose